CA2612497C - Process for the preparation of adapalene and related compounds - Google Patents
Process for the preparation of adapalene and related compounds Download PDFInfo
- Publication number
- CA2612497C CA2612497C CA2612497A CA2612497A CA2612497C CA 2612497 C CA2612497 C CA 2612497C CA 2612497 A CA2612497 A CA 2612497A CA 2612497 A CA2612497 A CA 2612497A CA 2612497 C CA2612497 C CA 2612497C
- Authority
- CA
- Canada
- Prior art keywords
- adapalene
- salt
- dimethoxybiphenyl
- diadamantyl
- purity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
- C07C65/26—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/02—Preparation of carboxylic acids or their salts, halides or anhydrides from salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/50—Use of additives, e.g. for stabilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
- C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
The invention relates to the use of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a marker for assessing the purity of adapalene, adapalene methyl ester, an adapalene salt and pharmaceutical compositions containing adapalene, to methods for assessing the purity thereof and to methods for their purification.
Description
= 54107-3 PROCESS FOR THE PREPARATION OF ADAPALENE AND RELATED
COMPOUNDS
= BACKGROUND OF THE INVENTION
1. Field of the Invention 5 The invention provides an improved process for the preparation of a benzonaphthalene derivative. More particularly, the invention provides an improved process for the manufacture of high purity adapalene. The invention further includes a method for assessing the color of adapalene by means of a quantitative colorimetric = measurement of the solid adapalene.
10 2. Relevant Background The chemical name for adapalene is 643-(1-adamanty1)-4-methoxyphenyl]-2-=
naphthoic acid, which is represented by Compound I (below):
Lir Nis Compound I
15 Adapalene has been approved by the FDA as a cream, a gel, a solution and pledgets for the topical treatment of acne vulgaris and is marketed under the tradename ofDiFFERIN .
United States Patent No. 4,717,720 ("the '720 patent") discloses benzonaphthalene derivatives, including adapalene. The '720 patent describes a process for preparing adapalene (i.e., according to example 9c followed by example 10) that involves two reaction steps.
The first step for preparing adapalene according to the '720 patent involves the preparation of the methyl ester of 643-(1-adamanty1)-4-methoxy phenyl]-2-naphthoic acid.
According to example 9c of the '720 patent, 2-(1-adamanty1)-4-bromoanisole (also known as 1-(5-bromo-2-methoxyphenyl)adamantane) is converted to its organomagnesium derivative and then into its organozinc derivative. The organozinc derivative is next coupled to methyl 6-bromo-2-naphthoate by adding a catalytic amount of NiC12/DPPE complex (also known as [bis(diphenylphosphino) ethane]dichloronickel(ll)). Upon completion of the reaction, the mixture is poured into water, extracted with dichloromethane, and then dried. The product is next isolated by column chromatography by eluting with a mixture of heptane (70%) and dichloromethane (30%). The resulting product is then recrystallized in ethyl acetate (yield: 78%).
The second step for preparing adapalene according to the '720 patent involves hydrolyzing the product of step 1 (above). According to example 10 of the '720 patent, the ester obtained in Example 9c can be treated with a solution of soda in methanol followed by heating at reflux for 48 hours. The solvents are then evaporated and the resulting residue is taken up in water and acidified with concentrated HC1 to neutralize the resulting adapalene sodium salt. The resulting solid is next filtered and dried under vacuum over phosphoric anhydride and then recrystallized in a mixture of tetrahydrofium and ethyl acetate to yield adapalene (yield: 81%).
The process of preparing adapalene according to the '720 patent is both difficult and uneconomical to conduct on an industrial scale. Regarding step 1, the use of dichloromethane is both toxic and hazardous for the environment. Additionally, purification of the intermediate product by column chromatography, followed by recrystallization, in order to obtain a crystalline product of acceptable purity is both expensive and laborious. Moreover, the step 1 process produces as a biaryllic C-C bond, and the catalytic coupling is noticeably exothermic. Regarding step 2, the synthesis of adapalene and/or its sodium salt requires a long reaction time (i.e., 48 hours) at methanol reflux and further requires a high ratio of solvent (volume) to product (mass).
COMPOUNDS
= BACKGROUND OF THE INVENTION
1. Field of the Invention 5 The invention provides an improved process for the preparation of a benzonaphthalene derivative. More particularly, the invention provides an improved process for the manufacture of high purity adapalene. The invention further includes a method for assessing the color of adapalene by means of a quantitative colorimetric = measurement of the solid adapalene.
10 2. Relevant Background The chemical name for adapalene is 643-(1-adamanty1)-4-methoxyphenyl]-2-=
naphthoic acid, which is represented by Compound I (below):
Lir Nis Compound I
15 Adapalene has been approved by the FDA as a cream, a gel, a solution and pledgets for the topical treatment of acne vulgaris and is marketed under the tradename ofDiFFERIN .
United States Patent No. 4,717,720 ("the '720 patent") discloses benzonaphthalene derivatives, including adapalene. The '720 patent describes a process for preparing adapalene (i.e., according to example 9c followed by example 10) that involves two reaction steps.
The first step for preparing adapalene according to the '720 patent involves the preparation of the methyl ester of 643-(1-adamanty1)-4-methoxy phenyl]-2-naphthoic acid.
According to example 9c of the '720 patent, 2-(1-adamanty1)-4-bromoanisole (also known as 1-(5-bromo-2-methoxyphenyl)adamantane) is converted to its organomagnesium derivative and then into its organozinc derivative. The organozinc derivative is next coupled to methyl 6-bromo-2-naphthoate by adding a catalytic amount of NiC12/DPPE complex (also known as [bis(diphenylphosphino) ethane]dichloronickel(ll)). Upon completion of the reaction, the mixture is poured into water, extracted with dichloromethane, and then dried. The product is next isolated by column chromatography by eluting with a mixture of heptane (70%) and dichloromethane (30%). The resulting product is then recrystallized in ethyl acetate (yield: 78%).
The second step for preparing adapalene according to the '720 patent involves hydrolyzing the product of step 1 (above). According to example 10 of the '720 patent, the ester obtained in Example 9c can be treated with a solution of soda in methanol followed by heating at reflux for 48 hours. The solvents are then evaporated and the resulting residue is taken up in water and acidified with concentrated HC1 to neutralize the resulting adapalene sodium salt. The resulting solid is next filtered and dried under vacuum over phosphoric anhydride and then recrystallized in a mixture of tetrahydrofium and ethyl acetate to yield adapalene (yield: 81%).
The process of preparing adapalene according to the '720 patent is both difficult and uneconomical to conduct on an industrial scale. Regarding step 1, the use of dichloromethane is both toxic and hazardous for the environment. Additionally, purification of the intermediate product by column chromatography, followed by recrystallization, in order to obtain a crystalline product of acceptable purity is both expensive and laborious. Moreover, the step 1 process produces as a biaryllic C-C bond, and the catalytic coupling is noticeably exothermic. Regarding step 2, the synthesis of adapalene and/or its sodium salt requires a long reaction time (i.e., 48 hours) at methanol reflux and further requires a high ratio of solvent (volume) to product (mass).
2 Additionally, according to the prior art, the manufacture of adapalene is not satisfactory for industrial implementation because the presence of high amounts of undesired by-products makes it necessary to use uneconomical purification procedures to isolate the product according to quality specifications. One significant undesired by-product produced during the Grignard reaction of step 1 in the synthesis of adapalene is 3,3'-diadamanty1-4,4'-dimethoxybiphenyl, which has not been previously described in the literature and which is represented by Compound VI (below):
CH,0 OCH, Compound VI
The level of the by-product in a sample of adapalene, adapalene methyl ester and/or an adapalene salt can be determined using standard analytical techniques known to those of ordinary skill in the art. For example, the level can be determined by HPLC. A
specific method for determining the level of this impurity is provided herein.
Since the solubility of the dimeric by-product is very low in most solvents, the design of an economical industrial process that yields pure adapalene without the use of expensive chromatographic methods requires the selection of the proper solvents and conditions to inhibit formation of the by-product during the manufacturing process.
Additionally, adapalene has been described as being white (see, e.g., Merck Index, 13th ed., p. 29). It has been observed that adapalene has a tendency to yellow under certain synthetic conditions or due to the quality of the starting materials used in its preparation. In this regard, color must be attributed to the presence of some specific impurities that may or may not be detectable by conventional methods such as FIPLC.
CH,0 OCH, Compound VI
The level of the by-product in a sample of adapalene, adapalene methyl ester and/or an adapalene salt can be determined using standard analytical techniques known to those of ordinary skill in the art. For example, the level can be determined by HPLC. A
specific method for determining the level of this impurity is provided herein.
Since the solubility of the dimeric by-product is very low in most solvents, the design of an economical industrial process that yields pure adapalene without the use of expensive chromatographic methods requires the selection of the proper solvents and conditions to inhibit formation of the by-product during the manufacturing process.
Additionally, adapalene has been described as being white (see, e.g., Merck Index, 13th ed., p. 29). It has been observed that adapalene has a tendency to yellow under certain synthetic conditions or due to the quality of the starting materials used in its preparation. In this regard, color must be attributed to the presence of some specific impurities that may or may not be detectable by conventional methods such as FIPLC.
3 SUMMARY OF THE INVENTION
The invention provides an improved process for the preparation of a benzonaphthalene derivative. More particularly, the invention provides an improved process for the manufacture of high purity adapalene. The invention further includes a method for assessing the color of adapalene by means of a quantitative colorimetric measurement of the solid adapalene.
Another aspect of the invention includes a method for assessing the purity of adapalene by means of a quantitative colorimetzic measurement of the solid adapalene. This method consists in using a colorimeter or spectrophotometer apparatus to measure the L*, a*
and b* coordinates of the solid sample of adapalene. Thus, the color of the solid sample is located in the CIE 1976 L*, a*, b* Color Space (ClELAB; CIE stands for Commission Internationale de l'Eclairage or International Commission on Illumination).
The three parameters in the model represent the lightness of the color (i.e., L*, an L*
=0 indicates black and an L* = 100 indicates white), its position between magenta and green (i.e., a*, negative values indicate green while positive values indicate magenta) and its position between yellow and blue (i.e., b*, negative values indicate blue and positive values indicate yellow).
Thus, the process of preparing adapalene according to the invention provides adapalene that is white by visual inspection and this fact is corroborated by the colorimeiric measurements that yield values in the CitLAB color space that are very close to the values of =
absolute white that are L* = 100; a *= 0; b* 0. See, e.g., US Pharmacopoeia 29th ed., General Chapter 1061, p. 2896.
The invention provides an improved process for the preparation of a benzonaphthalene derivative. More particularly, the invention provides an improved process for the manufacture of high purity adapalene. The invention further includes a method for assessing the color of adapalene by means of a quantitative colorimetric measurement of the solid adapalene.
Another aspect of the invention includes a method for assessing the purity of adapalene by means of a quantitative colorimetzic measurement of the solid adapalene. This method consists in using a colorimeter or spectrophotometer apparatus to measure the L*, a*
and b* coordinates of the solid sample of adapalene. Thus, the color of the solid sample is located in the CIE 1976 L*, a*, b* Color Space (ClELAB; CIE stands for Commission Internationale de l'Eclairage or International Commission on Illumination).
The three parameters in the model represent the lightness of the color (i.e., L*, an L*
=0 indicates black and an L* = 100 indicates white), its position between magenta and green (i.e., a*, negative values indicate green while positive values indicate magenta) and its position between yellow and blue (i.e., b*, negative values indicate blue and positive values indicate yellow).
Thus, the process of preparing adapalene according to the invention provides adapalene that is white by visual inspection and this fact is corroborated by the colorimeiric measurements that yield values in the CitLAB color space that are very close to the values of =
absolute white that are L* = 100; a *= 0; b* 0. See, e.g., US Pharmacopoeia 29th ed., General Chapter 1061, p. 2896.
4 According to another aspect of the present invention, there is provided the use of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a marker for assessing the purity of at least one of adapalene, adapalene methyl ester, an adapalene salt and pharmaceutical compositions containing adapalene.
According to still another aspect of the present invention, there is provided a method for assessing the purity of at least one of adapalene, adapalene methyl ester, an adapalene salt and pharmaceutical compositions containing them comprising the steps of:
(a) providing a standard solution of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl;
and (b) using the solution as reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity.
According to yet another aspect of the present invention, there is provided a method for purifying adapalene, or a salt thereof, suitable for pharmaceutical use, comprising the steps of: (a) providing adapalene, or a salt thereof; (b) assessing the purity of said adapalene, or salt thereof, by using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity; and (c) subjecting the adapalene, or a salt thereof, to one or more purification steps until the 3,3%
diadamanty1-4,4'-dimethoxybiphenyl is not detected, when analyzed according to reverse phase HPLC.
According to a further aspect of the present invention, there is provided a method for purifying adapalene, or salt thereof, suitable for pharmaceutical use, comprising the steps of: (a) providing adapalene, or a salt thereof; (b) assessing the purity of said adapalene, or salt thereof, by using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity; and (c) subjecting the adapalene, or salt thereof, to one or more purification steps; wherein step (c) is performed either before or after step (b).
According to yet a further aspect of the present invention, there is provided a method for preparing adapalene suitable for pharmaceutical use comprising: (a) preparing adapalene methyl ester; (b) hydrolyzing said adapalene methyl ester to yield adapalene salt;
4a (c) converting said adapalene salt into adapalene; (d) isolating said adapalene; and (e) assessing the purity of at least one of adapalene, adapalene methyl ester, and adapalene salt, by using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity.
According to still a further aspect of the present invention, there is provided a method for preparing adapalene suitable for pharmaceutical use comprising: (a) preparing an adapalene salt; (b) converting said adapalene salt into adapalene; (c) isolating said adapalene;
and (d) assessing the purity of at least one of adapalene and adapalene salt, by using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity.
According to yet another aspect of the present invention there is provided a method for determining the purity of adapalene suitable for pharmaceutical use, said method comprising: (a) producing adapalene; (b) quantifying the amount of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl in a sample of the adapalene, using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker; and (c) verifying that the adapalene produced in step (a) is suitable for pharmaceutical use, by determining that the sample measured in step (b) has no detectable amount of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl with respect to adapalene, when analyzed according to reverse phase HPLC.
According to yet another aspect of the present invention, there is provided a method for producing adapalene suitable for pharmaceutical use, said method comprising: (a) preparing adapalene salt; (c) converting said adapalene salt into adapalene;
(d) isolating said adapalene; (e) quantifying the amount of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl in a sample of the isolated adapalene, using a standard solution of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker; and (f) verifying that the adapalene isolated in step (d) is suitable for pharmaceutical use, by determining that the sample measured in step (e) has no detectable amount of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl with respect to adapalene, when analyzed according to reverse phase HPLC.
4b , , According to yet another aspect of the present invention, there is provided a method for preparing adapalene suitable for pharmaceutical use comprising: (a) providing an adapalene salt containing 3,3'-diadamanty1-4,4'-dimethoxybiphenyl; (b) purifying the adapalene salt to a purity of more than 99.8% when analyzed according to reverse phase high performance liquid chromatography with respect to 3,3'-diadamanty1-4,4'-dimethoxybiphenyl; (c) neutralizing the resulting adapalene salt; and (d) isolating from the neutralized salt said adapalene suitable for pharmaceutical use.
According to yet another aspect of the present invention, there is provided a method for preparing adapalene suitable for pharmaceutical use comprising: (a) providing adapalene methyl ester containing 3,3'-diadamanty1-4,4'-dimethoxybiphenyl; (b) converting the adapalene methyl ester to an adapalene salt having a purity of more than 99.8% when analyzed according to reverse phase high performance liquid chromatography with respect to 3,3'-diadamanty1-4,4'-dimethoxybiphenyl; (c) neutralizing the resulting adapalene salt; and (d) isolating from the neutralized salt said adapalene suitable for pharmaceutical use.
BRIEF DESCRIPTION OF THE DRAWING
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention. In the drawings:
4c Figure 1 illustrates the X-ray diffractogram of adapalene made in by the process of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Reference will now be made in detail to the preferred embodiments of the invention.
This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. In addition and as will be appreciated by one of skill in the art, the invention may be embodied as a method, system or process.
The invention provides an improved process for preparing adapalene. In particular, the invention provides an improved process for preparing adapalene that includes isolating adapalene potassium salt. As illustrated in Scheme 1 (below), the process of the invention includes three reaction steps.
The first step ("step 1") of the process of the invention involves the preparation of the adapalene methyl ester as described in detail below in Example/Step 1.
According to the process of the invention, step 1 includes charging the catalyst (NiC12/DPPE complex) prior to the addition of methyl 6-bromo-2-naphthoate. Doing so provides better control of the reaction and thus helps minimize the generation of heat. In particular, addition of the methyl 6-bromo-2-naphthoate over a suspension of the organozinc derivative and the catalyst minimizes the exothermic reaction and associated risks at the industrial scale.
Additionally, step 1 of the process of the invention is considerably less laborious that known procedures. In particular, the product is isolated by filtration as a solid from the reaction mixture, thus avoiding the use of dichloromethane (which also results in extraction of impurities). Once isolated, the solid product can be purified by suspending/recrystallizing it in an organic solvent (e.g., an aromatic hydrocarbon solvent, a ketone solvent, an ether solvent, an alcohol solvent, an ester solvent, water and/or mixtures thereof) therefore avoiding the need to purify the product by column chromatography. Preferable solvents include methyl ethyl ketone and/or mixtures of tetrahydrofuran and water.
According to still another aspect of the present invention, there is provided a method for assessing the purity of at least one of adapalene, adapalene methyl ester, an adapalene salt and pharmaceutical compositions containing them comprising the steps of:
(a) providing a standard solution of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl;
and (b) using the solution as reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity.
According to yet another aspect of the present invention, there is provided a method for purifying adapalene, or a salt thereof, suitable for pharmaceutical use, comprising the steps of: (a) providing adapalene, or a salt thereof; (b) assessing the purity of said adapalene, or salt thereof, by using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity; and (c) subjecting the adapalene, or a salt thereof, to one or more purification steps until the 3,3%
diadamanty1-4,4'-dimethoxybiphenyl is not detected, when analyzed according to reverse phase HPLC.
According to a further aspect of the present invention, there is provided a method for purifying adapalene, or salt thereof, suitable for pharmaceutical use, comprising the steps of: (a) providing adapalene, or a salt thereof; (b) assessing the purity of said adapalene, or salt thereof, by using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity; and (c) subjecting the adapalene, or salt thereof, to one or more purification steps; wherein step (c) is performed either before or after step (b).
According to yet a further aspect of the present invention, there is provided a method for preparing adapalene suitable for pharmaceutical use comprising: (a) preparing adapalene methyl ester; (b) hydrolyzing said adapalene methyl ester to yield adapalene salt;
4a (c) converting said adapalene salt into adapalene; (d) isolating said adapalene; and (e) assessing the purity of at least one of adapalene, adapalene methyl ester, and adapalene salt, by using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity.
According to still a further aspect of the present invention, there is provided a method for preparing adapalene suitable for pharmaceutical use comprising: (a) preparing an adapalene salt; (b) converting said adapalene salt into adapalene; (c) isolating said adapalene;
and (d) assessing the purity of at least one of adapalene and adapalene salt, by using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity.
According to yet another aspect of the present invention there is provided a method for determining the purity of adapalene suitable for pharmaceutical use, said method comprising: (a) producing adapalene; (b) quantifying the amount of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl in a sample of the adapalene, using 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker; and (c) verifying that the adapalene produced in step (a) is suitable for pharmaceutical use, by determining that the sample measured in step (b) has no detectable amount of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl with respect to adapalene, when analyzed according to reverse phase HPLC.
According to yet another aspect of the present invention, there is provided a method for producing adapalene suitable for pharmaceutical use, said method comprising: (a) preparing adapalene salt; (c) converting said adapalene salt into adapalene;
(d) isolating said adapalene; (e) quantifying the amount of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl in a sample of the isolated adapalene, using a standard solution of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl as a reference marker; and (f) verifying that the adapalene isolated in step (d) is suitable for pharmaceutical use, by determining that the sample measured in step (e) has no detectable amount of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl with respect to adapalene, when analyzed according to reverse phase HPLC.
4b , , According to yet another aspect of the present invention, there is provided a method for preparing adapalene suitable for pharmaceutical use comprising: (a) providing an adapalene salt containing 3,3'-diadamanty1-4,4'-dimethoxybiphenyl; (b) purifying the adapalene salt to a purity of more than 99.8% when analyzed according to reverse phase high performance liquid chromatography with respect to 3,3'-diadamanty1-4,4'-dimethoxybiphenyl; (c) neutralizing the resulting adapalene salt; and (d) isolating from the neutralized salt said adapalene suitable for pharmaceutical use.
According to yet another aspect of the present invention, there is provided a method for preparing adapalene suitable for pharmaceutical use comprising: (a) providing adapalene methyl ester containing 3,3'-diadamanty1-4,4'-dimethoxybiphenyl; (b) converting the adapalene methyl ester to an adapalene salt having a purity of more than 99.8% when analyzed according to reverse phase high performance liquid chromatography with respect to 3,3'-diadamanty1-4,4'-dimethoxybiphenyl; (c) neutralizing the resulting adapalene salt; and (d) isolating from the neutralized salt said adapalene suitable for pharmaceutical use.
BRIEF DESCRIPTION OF THE DRAWING
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention. In the drawings:
4c Figure 1 illustrates the X-ray diffractogram of adapalene made in by the process of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Reference will now be made in detail to the preferred embodiments of the invention.
This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. In addition and as will be appreciated by one of skill in the art, the invention may be embodied as a method, system or process.
The invention provides an improved process for preparing adapalene. In particular, the invention provides an improved process for preparing adapalene that includes isolating adapalene potassium salt. As illustrated in Scheme 1 (below), the process of the invention includes three reaction steps.
The first step ("step 1") of the process of the invention involves the preparation of the adapalene methyl ester as described in detail below in Example/Step 1.
According to the process of the invention, step 1 includes charging the catalyst (NiC12/DPPE complex) prior to the addition of methyl 6-bromo-2-naphthoate. Doing so provides better control of the reaction and thus helps minimize the generation of heat. In particular, addition of the methyl 6-bromo-2-naphthoate over a suspension of the organozinc derivative and the catalyst minimizes the exothermic reaction and associated risks at the industrial scale.
Additionally, step 1 of the process of the invention is considerably less laborious that known procedures. In particular, the product is isolated by filtration as a solid from the reaction mixture, thus avoiding the use of dichloromethane (which also results in extraction of impurities). Once isolated, the solid product can be purified by suspending/recrystallizing it in an organic solvent (e.g., an aromatic hydrocarbon solvent, a ketone solvent, an ether solvent, an alcohol solvent, an ester solvent, water and/or mixtures thereof) therefore avoiding the need to purify the product by column chromatography. Preferable solvents include methyl ethyl ketone and/or mixtures of tetrahydrofuran and water.
5 The second step ("step 2") of the process of the invention involves the hydrolysis of the adapalene methyl ester to yield adapalene potassium salt. According to the process of the invention, step 2 includes performing the hydrolysis in the presence of a phase transfer catalyst in an aromatic apolar solvent (e.g., toluene). Performing the hydrolysis under these conditions reduces the reaction time from 48 hours to approximately 2 to 3 hours.
Additionally, the adapalene potassium salt prepared in step 2 can be recovered from the reaction mixture by filtration. Importantly, the homocoupling product (i.e., 3,3'-diadamanty1-4,4'-dimethoxy biphenyl, Compound VI) is more soluble in aromatic apolar solvents (e.g., toluene) than the corresponding potassium salt. Thus, elimination of most, if not all, of the by-product is achieved via filtration. The adapalene potassium salt can optionally be purified by suspending/recrystallizing it in an organic solvent (e.g., an aromatic solvent, an ether solvent, a mixture of an alcohol and water and/or mixtures thereof).
It is believed that step 2 of the process of the invention can be performed using other adapalene salts other than the potassium salt. Such additional adapalene salts include, for example, the sodium salt, the lithium salt, the cesium salt and/or other salts arising from other bases that could alternatively be used for hydrolyzing the adapalene methyl ester.
The third step ("step 3") of the process of the invention involves the neutralization of the adapalene potassium salt to yield adapalene. According to the process of the invention, step 3 includes performing the neutralization in an alcoholic solvent, which facilitates the neutrali7ation and avoids solid-solid occlusions. Additionally, the neuiralintion is performed at a temperature not exceeding than 40 C in order to prevent the unwanted esterification of the adapalene product.
In step 3 of the process of the invention, insolubles can optionally be removed by filtration and decolorizing agents can optionally be employed to improve the color of the crude adapalene. Such steps can be performed in, for example, tetrahydrofuran and/or mixtures of tetrahydrofuran and water. Suitable decolorizing agents can be any conventional decolorizing agent, including, for example, alumina, activated alumina, silica, a metabisulphite salt and charcoal. The preferred decolorizing agent is a sulfur based reducing agent including, for example, metabisulfphite or dithionite salts.
Partial distillation of the tetrahydrofuran and, optionally, addition of a protic solvent (e.g., methanol or water) yields the desired crystalline product.
Additionally, the adapalene potassium salt prepared in step 2 can be recovered from the reaction mixture by filtration. Importantly, the homocoupling product (i.e., 3,3'-diadamanty1-4,4'-dimethoxy biphenyl, Compound VI) is more soluble in aromatic apolar solvents (e.g., toluene) than the corresponding potassium salt. Thus, elimination of most, if not all, of the by-product is achieved via filtration. The adapalene potassium salt can optionally be purified by suspending/recrystallizing it in an organic solvent (e.g., an aromatic solvent, an ether solvent, a mixture of an alcohol and water and/or mixtures thereof).
It is believed that step 2 of the process of the invention can be performed using other adapalene salts other than the potassium salt. Such additional adapalene salts include, for example, the sodium salt, the lithium salt, the cesium salt and/or other salts arising from other bases that could alternatively be used for hydrolyzing the adapalene methyl ester.
The third step ("step 3") of the process of the invention involves the neutralization of the adapalene potassium salt to yield adapalene. According to the process of the invention, step 3 includes performing the neutralization in an alcoholic solvent, which facilitates the neutrali7ation and avoids solid-solid occlusions. Additionally, the neuiralintion is performed at a temperature not exceeding than 40 C in order to prevent the unwanted esterification of the adapalene product.
In step 3 of the process of the invention, insolubles can optionally be removed by filtration and decolorizing agents can optionally be employed to improve the color of the crude adapalene. Such steps can be performed in, for example, tetrahydrofuran and/or mixtures of tetrahydrofuran and water. Suitable decolorizing agents can be any conventional decolorizing agent, including, for example, alumina, activated alumina, silica, a metabisulphite salt and charcoal. The preferred decolorizing agent is a sulfur based reducing agent including, for example, metabisulfphite or dithionite salts.
Partial distillation of the tetrahydrofuran and, optionally, addition of a protic solvent (e.g., methanol or water) yields the desired crystalline product.
6
7 PCT/1B2006/003987 Scheme 1 illustrates the preparation of adapalene prepared according to one aspect of the invention.
go, 0 148r ZnC6 Clip- '.----L' -. cfµ.
filit II
III
.60 -0 rai 4.
iic,i c.
,* *0 w CHp leg I
Scheme 1 Scheme 1 legend:
Compound Name a.
J.4.- offatc, Et two: rarmir. - egiQD *
I Adapalene II 1-(5-Bromo-2-Methoxyphenyl)Adamantane III 6-Bromo-2-Naphthoate IV Methyl 643-(1-adamanty1)-4-Methoxypheny1]-2-Naphthoate 643-(1-Adamanty1)-4-Methoxypheny1]-2-Naphthoic Acid Potassium V
Salt One aspect of the invention includes a process for preparing adapalene from a corresponding salt.
Another aspect of the invention includes a process for preparing adapalene methyl ester.
Another aspect of the invention includes adapalene salts and a process for preparing them.
Another aspect of the invention includes purifying/crystallizing adapalene salts.
Another aspect of the invention includes a process for preparing adapalene from its corresponding potassium salt.
Another aspect of the invention includes the 3,3'-diadamanty1-4,4'-dimethoxybiphenyl by-product (Compound VI, above) and its use as a reference marker for the assessment of the quality of adapalene and/or pharmaceutical compositions containing adapalene.
Another aspect of the invention includes the use of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl by-product (Compound VI, above) as a reference marker for evaluating the quality of an adapalene methyl ester intermediate.
Another aspect of the invention includes the use of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl by-product (Compound VI, above) as a reference marker for measuring the quality of an adapalene salt intermediate.
Another aspect of the invention includes charging the NiC12/DPPE complex before the addition of methyl 6-bromo-2-naphthoate in the catalytic coupling step.
Another aspect of the invention includes washing adapalene methyl ester with a solvent that includes an aromatic hydrocarbon solvent, a ketone solvent, an ether solvent, an alcohol solvent, an ester solvent, water and/or mixtures thereof, thus avoiding the need to purify the product by column chromatography. Preferable solvents include methyl ethyl ketone and/or mixtures of tetrahydrofuran and water.
Another aspect of the invention includes using a phase transfer catalyst and a base to hydrolyze adapalene methyl ester.
Another aspect of the invention includes using a phase transfer catalyst and an inorganic base to hydrolyze adapalene methyl ester.
Another aspect of the invention includes using a phase transfer catalyst and an inorganic base, preferably an alkali hydroxide, to hydrolyze adapalene methyl ester.
Another aspect of the invention includes using a phase transfer catalyst and an inorganic base, preferably an alkali hydroxide, and most preferably potassium hydroxide, to hydrolyze adapalene methyl ester.
go, 0 148r ZnC6 Clip- '.----L' -. cfµ.
filit II
III
.60 -0 rai 4.
iic,i c.
,* *0 w CHp leg I
Scheme 1 Scheme 1 legend:
Compound Name a.
J.4.- offatc, Et two: rarmir. - egiQD *
I Adapalene II 1-(5-Bromo-2-Methoxyphenyl)Adamantane III 6-Bromo-2-Naphthoate IV Methyl 643-(1-adamanty1)-4-Methoxypheny1]-2-Naphthoate 643-(1-Adamanty1)-4-Methoxypheny1]-2-Naphthoic Acid Potassium V
Salt One aspect of the invention includes a process for preparing adapalene from a corresponding salt.
Another aspect of the invention includes a process for preparing adapalene methyl ester.
Another aspect of the invention includes adapalene salts and a process for preparing them.
Another aspect of the invention includes purifying/crystallizing adapalene salts.
Another aspect of the invention includes a process for preparing adapalene from its corresponding potassium salt.
Another aspect of the invention includes the 3,3'-diadamanty1-4,4'-dimethoxybiphenyl by-product (Compound VI, above) and its use as a reference marker for the assessment of the quality of adapalene and/or pharmaceutical compositions containing adapalene.
Another aspect of the invention includes the use of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl by-product (Compound VI, above) as a reference marker for evaluating the quality of an adapalene methyl ester intermediate.
Another aspect of the invention includes the use of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl by-product (Compound VI, above) as a reference marker for measuring the quality of an adapalene salt intermediate.
Another aspect of the invention includes charging the NiC12/DPPE complex before the addition of methyl 6-bromo-2-naphthoate in the catalytic coupling step.
Another aspect of the invention includes washing adapalene methyl ester with a solvent that includes an aromatic hydrocarbon solvent, a ketone solvent, an ether solvent, an alcohol solvent, an ester solvent, water and/or mixtures thereof, thus avoiding the need to purify the product by column chromatography. Preferable solvents include methyl ethyl ketone and/or mixtures of tetrahydrofuran and water.
Another aspect of the invention includes using a phase transfer catalyst and a base to hydrolyze adapalene methyl ester.
Another aspect of the invention includes using a phase transfer catalyst and an inorganic base to hydrolyze adapalene methyl ester.
Another aspect of the invention includes using a phase transfer catalyst and an inorganic base, preferably an alkali hydroxide, to hydrolyze adapalene methyl ester.
Another aspect of the invention includes using a phase transfer catalyst and an inorganic base, preferably an alkali hydroxide, and most preferably potassium hydroxide, to hydrolyze adapalene methyl ester.
8 Another aspect of the invention includes using a phase transfer catalyst to hydrolyze adapalene methyl ester, where the phase transfer catalyst is a quaternary ammonium salt.
Another aspect of the invention includes using a phase transfer catalyst to hydrolyze adapalene methyl ester, where the phase transfer catalyst is a quaternary ammonium salt, preferably a tetraalkylammonium halide and, most preferably, tetrabutylammonium bromide.
Another aspect of the invention includes using an apolar solvent, preferably an aromatic apolar solvent, and most preferably toluene to hydrolyze adapalene methyl ester.
Another aspect of the invention includes using a reaction time of less than approximately 3 hours to hydrolyze adapalene methyl ester.
Another aspect of the invention includes washing an adapalene salt with a solvent, including, for example, an aromatic hydrocarbon, esters, ethers, ketones, alcohols and water or a mixture thereof, and, preferably, mixtures of tetrahydrofuran and toluene and/or mixtures of methanol and water.
Another aspect of the invention includes using adapalene methyl ester that contains variable amounts of dimeric compound of Compound VI when hydrolyzing adapalene methyl ester.
Another aspect of the invention includes purifying adapalene by decolorizing and/or filtering a dissolution of adapalene.
Another aspect of the invention includes using methanol when neutralizing an adapalene salt.
Another aspect of the invention includes removing by filtration any insoluble particles of a solution of adapalene in tetrahydrofuran.
Another aspect of the invention includes decolorizing adapalene in tetrahydrofuran and, preferably, using a decolorizing agent that is a salt of metabisulphite and, more preferably, sodium metabisulphite.
Another aspect of the invention includes using a phase transfer catalyst to hydrolyze adapalene methyl ester, where the phase transfer catalyst is a quaternary ammonium salt, preferably a tetraalkylammonium halide and, most preferably, tetrabutylammonium bromide.
Another aspect of the invention includes using an apolar solvent, preferably an aromatic apolar solvent, and most preferably toluene to hydrolyze adapalene methyl ester.
Another aspect of the invention includes using a reaction time of less than approximately 3 hours to hydrolyze adapalene methyl ester.
Another aspect of the invention includes washing an adapalene salt with a solvent, including, for example, an aromatic hydrocarbon, esters, ethers, ketones, alcohols and water or a mixture thereof, and, preferably, mixtures of tetrahydrofuran and toluene and/or mixtures of methanol and water.
Another aspect of the invention includes using adapalene methyl ester that contains variable amounts of dimeric compound of Compound VI when hydrolyzing adapalene methyl ester.
Another aspect of the invention includes purifying adapalene by decolorizing and/or filtering a dissolution of adapalene.
Another aspect of the invention includes using methanol when neutralizing an adapalene salt.
Another aspect of the invention includes removing by filtration any insoluble particles of a solution of adapalene in tetrahydrofuran.
Another aspect of the invention includes decolorizing adapalene in tetrahydrofuran and, preferably, using a decolorizing agent that is a salt of metabisulphite and, more preferably, sodium metabisulphite.
9 Another aspect of the invention includes a partial distillation of tetrahydrofuran and filtration of the precipitated adapalene.
Another aspect of the invention includes a partial distillation of tetrahydrofuran and precipitation of adapalene that includes adding a protic solvent, preferably methanol or water.
Another aspect of the invention includes a process for preparing adapalene of high purity.
Another aspect of the invention includes a process for preparing adapalene of high purity and, preferably, where the adapalene is more than 99.8% pure when analyzed according to reverse phase high performance liquid chromatography and, more preferably, more than 99.9% pure when analyzed by reverse phase high performance liquid chromatography.
Another aspect of the invention includes a process for preparing adapalene of high purity where the adapalene is 100.0% pure when analyzed according to reverse phase high performance liquid chromatography.
Another aspect of the invention includes a process for preparing adapalene having a residue on ignition of less than 0.1% and, more preferably, less than 0.05%.
Another aspect of the invention includes using adapalene of high purity in the manufacture of pharmaceutical compositions.
Another aspect of the invention includes adapalene that is substantially white by visual inspection.
Another aspect of the invention includes substantially white adapalene having the following measurements in the CIE (1976) L*, a*, b* Color Space (CIELAB) when using a colorimeter or spectrophotometer, illuminant D65 (daylight) and a 2 angle of observation:
L* 98.5 to 100 a* -0.38 to -0.60 b* +0.31 to +0.93 =
-Another aspect of the invention includes substantially white adapalene having the following measurements in the CIE (1976) La*, b.* Color Space (CIELAB) when using a colorimeter or spectrophotometer, &mina* C and a 2 angle of observation:
L* 97.30 to 98.47 a* +0.20 to +0.45 b* 0.00 to -0.75 Another aspect of the invention includes a method for assessing the purity of adapalene by means of a quantitative colorimetric measurement of the solid advalene In this = method, the L*, a* and b* coordinates of a solid sample of adapalene are measured using a = colorimeter or spectrophotometer apparatus.
It will be apparent to those skilled in the art that various modifications and variations -=
can be made in the present invention and specific examples provided herein without departing from the scope of the invention. =
Specific Examples The following examples are for illustrative purposes only and are not intended, nor should they be interpreted to, limit the scope of the invention.
EXAMPLE/STEP 1: Preparation of Methyl 6-P-(1-adamanty1)-4-methoxy pheny11-2-naphthoate (Le., Adapalene Methyl Ester) To a 2 L, five-necked cylindrical reaction vessel equipped with a reflux condenser, heat-transfer jacket, compensated-pressure addition funnel, anchor impeller and purged with nitrogen, were added 1.13 g of 1-(5-bromo-2-methoxyphenyl) adamantane (3.52 x
Another aspect of the invention includes a partial distillation of tetrahydrofuran and precipitation of adapalene that includes adding a protic solvent, preferably methanol or water.
Another aspect of the invention includes a process for preparing adapalene of high purity.
Another aspect of the invention includes a process for preparing adapalene of high purity and, preferably, where the adapalene is more than 99.8% pure when analyzed according to reverse phase high performance liquid chromatography and, more preferably, more than 99.9% pure when analyzed by reverse phase high performance liquid chromatography.
Another aspect of the invention includes a process for preparing adapalene of high purity where the adapalene is 100.0% pure when analyzed according to reverse phase high performance liquid chromatography.
Another aspect of the invention includes a process for preparing adapalene having a residue on ignition of less than 0.1% and, more preferably, less than 0.05%.
Another aspect of the invention includes using adapalene of high purity in the manufacture of pharmaceutical compositions.
Another aspect of the invention includes adapalene that is substantially white by visual inspection.
Another aspect of the invention includes substantially white adapalene having the following measurements in the CIE (1976) L*, a*, b* Color Space (CIELAB) when using a colorimeter or spectrophotometer, illuminant D65 (daylight) and a 2 angle of observation:
L* 98.5 to 100 a* -0.38 to -0.60 b* +0.31 to +0.93 =
-Another aspect of the invention includes substantially white adapalene having the following measurements in the CIE (1976) La*, b.* Color Space (CIELAB) when using a colorimeter or spectrophotometer, &mina* C and a 2 angle of observation:
L* 97.30 to 98.47 a* +0.20 to +0.45 b* 0.00 to -0.75 Another aspect of the invention includes a method for assessing the purity of adapalene by means of a quantitative colorimetric measurement of the solid advalene In this = method, the L*, a* and b* coordinates of a solid sample of adapalene are measured using a = colorimeter or spectrophotometer apparatus.
It will be apparent to those skilled in the art that various modifications and variations -=
can be made in the present invention and specific examples provided herein without departing from the scope of the invention. =
Specific Examples The following examples are for illustrative purposes only and are not intended, nor should they be interpreted to, limit the scope of the invention.
EXAMPLE/STEP 1: Preparation of Methyl 6-P-(1-adamanty1)-4-methoxy pheny11-2-naphthoate (Le., Adapalene Methyl Ester) To a 2 L, five-necked cylindrical reaction vessel equipped with a reflux condenser, heat-transfer jacket, compensated-pressure addition funnel, anchor impeller and purged with nitrogen, were added 1.13 g of 1-(5-bromo-2-methoxyphenyl) adamantane (3.52 x
10-3 mol), 3.75 g of magnesium granules (1.54 x 104 mol) and 90 mL of tetrahydrofurtm.
Into the = compensated-pressure addition funnel was added a previously prepared solution of 36.37 g of 1-(5-bromo-2-methoxyphenyl)adamantane (1.13 x 104 mol) and 270 mL of tetrahydrofuran.
The reaction mixture was then heated to approximately 45 C, at which point 2.50 g of 1,2-
Into the = compensated-pressure addition funnel was added a previously prepared solution of 36.37 g of 1-(5-bromo-2-methoxyphenyl)adamantane (1.13 x 104 mol) and 270 mL of tetrahydrofuran.
The reaction mixture was then heated to approximately 45 C, at which point 2.50 g of 1,2-
11 dibromoethane (1.33 x 10-2 mol) was charged to the mixture. During the addition, the internal temperature increased and bubbling was observed, indicating initiation of the reaction.
At approximately 50 C, addition of the solution in the compensated-pressure addition funnel was initiated and continued over approximately 45 minutes during which time the internal temperature of the solution was maintained between approximately 50 and 55 C.
Following the addition, the reaction mixture was stirred for approximately 45 minutes at approximately 50 C
and then cooled to approximately 20-25 C. To the cooled suspension was added 18.18 g of anhydrous zinc chloride (1.33 x 104 mol) and an increase in temperature was observed within a few seconds. The mixture was permitted to cool and was stirred for approximately 1 hour at approximately 20-25 C. Thereafter, 1.05 g of 1,2-[bis(diphenylphosphino)ethane]
dichloronickel(I1) (2.20 x 10-3 mol) was charged to the reaction mixture followed by the addition of 24.00 g of methyl 6-bromo-2-naphtoate (9.05 x 10-2 mol). The mixture was permitted cool and was stirred for approximately two hours at room temperature.
Next, 50 NIL of water was slowly added and the mixture was stirred for approximately 15 minutes, at which point 200 mL of 1N HC1 was slowly added. The mixture was then stirred overnight at room temperature or until the excess of magnesium pellets were dissolved.
The mixture was then filtered, and the cake was washed with methyl ethyl ketone ("MEK").
The resulting solid was next suspended in 500 mL of 1N HC1 and 125 mL of WK.
The resulting suspension was then stirred at room temperature for approximately 1 hour. The mixture was then filtered, and the cake was washed with MEK. The resulting solid was next suspended in 270 mL of MEK and the mixture was heated to reflux for approximately 30 minutes, cooled and filtered. The resulting cake was then washed with MEK.
The wet solid obtained was suspended in 184 mL of tetrahydrofuran and was heated to approximately 50-60 C for approximately 30 minutes, cooled and precipitated by addition of 300 mL of methanol. The precipitate was then filtered and dried at approximately 60 C in a vacuum oven to yield 34.31 g of adapalene methyl ester (8.044 x 10-2 mol;
yield: 88.83%) as an off-white powder. Analytical data: HPLC Purity (}{PLC at 272 urn): 97.32%;
Impurity (i.e., 3,3'-diadamanty1-4,4'-dimethoxybiphenyl) area percent I-rpLC at 272 nm): 2.05%.
At approximately 50 C, addition of the solution in the compensated-pressure addition funnel was initiated and continued over approximately 45 minutes during which time the internal temperature of the solution was maintained between approximately 50 and 55 C.
Following the addition, the reaction mixture was stirred for approximately 45 minutes at approximately 50 C
and then cooled to approximately 20-25 C. To the cooled suspension was added 18.18 g of anhydrous zinc chloride (1.33 x 104 mol) and an increase in temperature was observed within a few seconds. The mixture was permitted to cool and was stirred for approximately 1 hour at approximately 20-25 C. Thereafter, 1.05 g of 1,2-[bis(diphenylphosphino)ethane]
dichloronickel(I1) (2.20 x 10-3 mol) was charged to the reaction mixture followed by the addition of 24.00 g of methyl 6-bromo-2-naphtoate (9.05 x 10-2 mol). The mixture was permitted cool and was stirred for approximately two hours at room temperature.
Next, 50 NIL of water was slowly added and the mixture was stirred for approximately 15 minutes, at which point 200 mL of 1N HC1 was slowly added. The mixture was then stirred overnight at room temperature or until the excess of magnesium pellets were dissolved.
The mixture was then filtered, and the cake was washed with methyl ethyl ketone ("MEK").
The resulting solid was next suspended in 500 mL of 1N HC1 and 125 mL of WK.
The resulting suspension was then stirred at room temperature for approximately 1 hour. The mixture was then filtered, and the cake was washed with MEK. The resulting solid was next suspended in 270 mL of MEK and the mixture was heated to reflux for approximately 30 minutes, cooled and filtered. The resulting cake was then washed with MEK.
The wet solid obtained was suspended in 184 mL of tetrahydrofuran and was heated to approximately 50-60 C for approximately 30 minutes, cooled and precipitated by addition of 300 mL of methanol. The precipitate was then filtered and dried at approximately 60 C in a vacuum oven to yield 34.31 g of adapalene methyl ester (8.044 x 10-2 mol;
yield: 88.83%) as an off-white powder. Analytical data: HPLC Purity (}{PLC at 272 urn): 97.32%;
Impurity (i.e., 3,3'-diadamanty1-4,4'-dimethoxybiphenyl) area percent I-rpLC at 272 nm): 2.05%.
12 The product may also contain a small amount of an unidentified impurity, which is more polar than the final product. This unidentified impurity, when observed, as well as the 3,3'-diadamanty1-4,4'-dimethoxybiphenyl impurity, are eliminated from the synthetic pathway during the work-up described in the Example/Step 2 (below).
EXAMPLE/STEP 2: Preparation of 643-(1-adamanty1)-4-methoxy pheny1]-2-naphthoic acid-potassium salt (i.e., Adapalene Potassium Salt) In a 2 L, five necked cylindrical reaction vessel equipped with reflux condenser, distillation kit, heat-transfer jacket, anchor impeller and purged with nitrogen, were added 48.38 g (dry equivalent amount) of methyl 6-[3-(1-adamanty1)-4-methoxypheny1]-1 0 naphtoate (1.134 x 104 mol), wet with methanol, 2.73 g of tetrabutylammonium bromide (8.47 x 10-3 mol), 18.39 g of potassium hydroxide (85% alkali content, freshly titrated. 2.79 x 104 mol) and 581 mL of toluene. The mixture was heated to reflux temperature, and the methanol/water was removed by distillation. The distilled mixture was replaced by pure toluene and the mixture was stirred at reflux for approximately three hours (including the time required for the distillation). The solution was then cooled to approximately 20-25 C, filtered and the resulting solid was washed with toluene.
The solid was next suspended in 187 mL of tetrahydrofuran and stirred for approximately 30 minutes. Then, 375 mL of toluene was added, and the mixture was heated to reflux and maintained at that temperature for approximately 1 hour. The solution was then cooled to approximately 20-25 C, filtered, and the resulting solid washed with toluene. , The toluene-wet product was then suspended in 256 mL of methanol, heated to reflux for approximately 30 minutes and cooled to 50-60 C. After cooling, 409 mL of water was added dropwise. The mixture was then again heated to reflux for approximately 15 additional minutes, cooled to room temperature and filtered. The resulting solid was washed with water to yield 50.69 g (wet) of adapalene potassium salt (1.12 x 104 mol, dry equivalent amount calculated from loss on drying; yield: 99.18%). Analytical data: HPLC Purity (I-rPLc at 272 nm): 99.86%; Impurity (i.e., 3,3'-diadamanty1-4,4'-dimethoxybiphenyl) area percent (HPLC at 272 urn): not detected; 1H-NMR (300 MHz, CD30D): 8 1.83 (broad s, 614), 2.08 (broad s, 3H), 2.21 (broad s, 614), 3.88 (s, 314), 7.04 (d, 111, J=8.4 Hz), 7.56 (overlapped, 1H, J= 2.4, 9.6 Hz), 7.57 (overlapped s, 1H), 7.74 (dd, 1H, J= 8.7, 1.8 Hz), 7.87 (d, 1H, J=
9.0 Hz), 7.97 (d,
EXAMPLE/STEP 2: Preparation of 643-(1-adamanty1)-4-methoxy pheny1]-2-naphthoic acid-potassium salt (i.e., Adapalene Potassium Salt) In a 2 L, five necked cylindrical reaction vessel equipped with reflux condenser, distillation kit, heat-transfer jacket, anchor impeller and purged with nitrogen, were added 48.38 g (dry equivalent amount) of methyl 6-[3-(1-adamanty1)-4-methoxypheny1]-1 0 naphtoate (1.134 x 104 mol), wet with methanol, 2.73 g of tetrabutylammonium bromide (8.47 x 10-3 mol), 18.39 g of potassium hydroxide (85% alkali content, freshly titrated. 2.79 x 104 mol) and 581 mL of toluene. The mixture was heated to reflux temperature, and the methanol/water was removed by distillation. The distilled mixture was replaced by pure toluene and the mixture was stirred at reflux for approximately three hours (including the time required for the distillation). The solution was then cooled to approximately 20-25 C, filtered and the resulting solid was washed with toluene.
The solid was next suspended in 187 mL of tetrahydrofuran and stirred for approximately 30 minutes. Then, 375 mL of toluene was added, and the mixture was heated to reflux and maintained at that temperature for approximately 1 hour. The solution was then cooled to approximately 20-25 C, filtered, and the resulting solid washed with toluene. , The toluene-wet product was then suspended in 256 mL of methanol, heated to reflux for approximately 30 minutes and cooled to 50-60 C. After cooling, 409 mL of water was added dropwise. The mixture was then again heated to reflux for approximately 15 additional minutes, cooled to room temperature and filtered. The resulting solid was washed with water to yield 50.69 g (wet) of adapalene potassium salt (1.12 x 104 mol, dry equivalent amount calculated from loss on drying; yield: 99.18%). Analytical data: HPLC Purity (I-rPLc at 272 nm): 99.86%; Impurity (i.e., 3,3'-diadamanty1-4,4'-dimethoxybiphenyl) area percent (HPLC at 272 urn): not detected; 1H-NMR (300 MHz, CD30D): 8 1.83 (broad s, 614), 2.08 (broad s, 3H), 2.21 (broad s, 614), 3.88 (s, 314), 7.04 (d, 111, J=8.4 Hz), 7.56 (overlapped, 1H, J= 2.4, 9.6 Hz), 7.57 (overlapped s, 1H), 7.74 (dd, 1H, J= 8.7, 1.8 Hz), 7.87 (d, 1H, J=
9.0 Hz), 7.97 (d,
13 1H, J= 8.7 Hz), 8.00 (broad d, 1H, J= 0.9 Hz), 8.06 (dd, 1H, 8.4, J=1.8 Hz), 8.47 (broad d, 1H, J= 0.9 Hz);13C-NMR (75.4 MHz, CD30D): 5 30.6, 38.3, 41.8, 55.5, 113.3, 125.3, 126.4, 126.6, 127.8, 128.3, 130.0, 130.4, 133.0, 134.2, 136.1, 136.3, 139.7, 141.1, 159.9, 175.4.
EXAMPLE/STEP 3: Preparation of 6-[3-(1-adamanty1)-4-methoxy pheny11-2-naphthoic acid (i.e., Adapalene) In 500 mL of methanol was added 49.59 g (1.10 x 10-1 mol, dry equivalent amount) of the wet solid obtained in Example/Step 2, and the mixture was heated to reflux for 30 minutes and cooled to approximately 40 C. Next, 33.17 g of concentrated HC1 was slowly added over approximately 1 hour with gentle stirring in order to ensure homogeneity, followed by the slow addition of 248 mL of water. The resulting mixture was stirred for approximately 30 additional minutes at approximately 40 C and then cooled to room temperature, filtered and washed with methanol. The wet solid was then suspended with 1020 mL of tetrahydrofuran and heated to reflux for approximately 10 minutes or until complete dissolution. The solution was then cooled to approximately 35 C, the solid particles were removed by filtration, and the filter was washed with tetrahydrofuran.
The collected mother liquors were heated to reflux, and 654 g of tetrahydrofuran was removed by distillation. The mixture was then cooled to approximately 55-60 C. Thereafter, 650 mL of methanol was added over approximately 10 minutes, and the mixture heated to reflux for approximately 30 minutes, cooled, and filtered. The resulting solid was filtered with methanol and dried at 80 C in a vacuum oven to yield 40.54 g of adapalene (9.83 x 10-2 mol;
yield: 89.29% (from adapalene potassium salt); 88.56% (from adapalene methyl ester); and 78.67% (from methyl 6-bromo-2-naphthoate)). Analytical data: HPLC Purity (HPLC
at 272 nm): 100.00%; Assay: 99.99%; Residue on Ignition: 0.02%; IR: matches reference.
Table 1 (below) lists the peak assignments of the X-ray powder diffractogram of the adapalene obtained and are illustrated in Figure 1.
EXAMPLE/STEP 3: Preparation of 6-[3-(1-adamanty1)-4-methoxy pheny11-2-naphthoic acid (i.e., Adapalene) In 500 mL of methanol was added 49.59 g (1.10 x 10-1 mol, dry equivalent amount) of the wet solid obtained in Example/Step 2, and the mixture was heated to reflux for 30 minutes and cooled to approximately 40 C. Next, 33.17 g of concentrated HC1 was slowly added over approximately 1 hour with gentle stirring in order to ensure homogeneity, followed by the slow addition of 248 mL of water. The resulting mixture was stirred for approximately 30 additional minutes at approximately 40 C and then cooled to room temperature, filtered and washed with methanol. The wet solid was then suspended with 1020 mL of tetrahydrofuran and heated to reflux for approximately 10 minutes or until complete dissolution. The solution was then cooled to approximately 35 C, the solid particles were removed by filtration, and the filter was washed with tetrahydrofuran.
The collected mother liquors were heated to reflux, and 654 g of tetrahydrofuran was removed by distillation. The mixture was then cooled to approximately 55-60 C. Thereafter, 650 mL of methanol was added over approximately 10 minutes, and the mixture heated to reflux for approximately 30 minutes, cooled, and filtered. The resulting solid was filtered with methanol and dried at 80 C in a vacuum oven to yield 40.54 g of adapalene (9.83 x 10-2 mol;
yield: 89.29% (from adapalene potassium salt); 88.56% (from adapalene methyl ester); and 78.67% (from methyl 6-bromo-2-naphthoate)). Analytical data: HPLC Purity (HPLC
at 272 nm): 100.00%; Assay: 99.99%; Residue on Ignition: 0.02%; IR: matches reference.
Table 1 (below) lists the peak assignments of the X-ray powder diffractogram of the adapalene obtained and are illustrated in Figure 1.
14 peak peak position peak intensity background 1 9.9.4547 175.32198 42.94638 2 13.18338 239.32156 48.88440 3 14.87487 234.32591 47.91444
15.28319 573.40082 53.73505 5 16.37472 1207.21631 69.64595 6 16.54000 882.00000 68.42529 7 17.39657 110.88804 58.39248 8 17.93203 114.02068 55.36037 9 19.44575 285.34473 113.52401 10 19.94692 569.60516 153.63921 11 22.43198 2846.14307 110.81189 12 24.02238 140.20882 85.37505 13 25.04586 925.64282 121.97974 14 25.41035 240.42351 102.81077 15 26.68556 362.45480 68.05973
16 27.71646 141.77916 72.53469
17 40.51307 133.00453 43.44914
18 46.52728 130.31587 50.16773 Table 1 EXAMPLE/STEP 4: Preparation of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl To a 100 mL rounded bottom reaction vessel equipped with a magnetic stirrer, thermometer, reflux condenser, pressure compensated addition funnel, were added 0.15 g of 145-bromo-2-methoxyphenyl)adamantane, 0.47 g of magnesium turnings and 7 mL of tetrahydrofuran.
The mixture was heated to approximately 35 C, and 0.13 mL of 1,2-dibromoethane were added to the mixture. Reaction exothermy self-heated the mixture. Next, a solution of 4.85 g of 145-bromo-2-methoxyphenyl)adamantane and 28 mL of tetrahydrofuran was added to the mixture dropwise. During this addition, the temperature of the mixture dropped from reflux temperature to approximately 45 C. The reaction was then stirred for approximately 45 additional minutes at approximately 45 C and was permitted to cool to approximately 22 C. Next, 2.3 g of ZnC12 was added to the mixture, resulting in an exothermic reaction that raised the temperature of the mixture to approximately 38 C. The mixture was then permitted to cool to approximately 22 C and was stirred for approximately 1 hour at this temperature.
Next, 0.03 g of Pd(OAc)2 and 3.5 g of 1-(5-bromo-2-methoxyphenyl) adamantane were added to the mixture, followed by 25 mL of tetrahydrofuran in order to improve agitation, and the mixture was heated at reflux for approximately 24 hours.
The resulting mixture was then evaporated to dryness and poured into 103 mL of 0.015 N HC1.
Next, 150 mL of dichloromethane and 100 mL of water were added to yield a mixture consisting of a solid, an aqueous layer and an organic layer. The mixture was then filtered to separate the solid, the aqueous layer was discarded, and the organic layer was washed with 200 mL of water and decanted again. This process was repeated twice on the filtered solid. The three collected organic layers were evaporated to dryness, washed in methanol, and dried to yield 2.1 g of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl (yield: 39.9%). Analytical data: Melting point: 288.1-289.1 C; Elemental analysis: C 83.63%, H 8.73%; 1H-NMR (300 MHz, CDC13):
8 1.78 (broad s, 12H), 2.08 (broad s, 6H), 2.15 (broad s, 12H), 3.86 (s, 61I), 6.92 (dm, 211, J=8.1 Hz), 7.34 (dd, 2H, J= 2.4, 8.1 Hz), 7.39 (d, 2H, J=2.4 Hz); 13C-NMR
(75.4 MHz, CDC13): 8 29.2, 37.1, 37.2, 40.6, 55.1, 111.9, 125.0, 125.5, 134.0, 138.5, 157.8; MS (El, 70eV): m/z= 484 (6), 483 (36), 412 (M+, 100), 410 (5), 347 (8), 135 (22), 107 (7), 93 (14), 79 (17), 67 (9), 55 (6); IR (Selected absorption bands): 2992, 2964, 2898, 2850, 1603 cm-1.
EXAMPLE 5: Colorimetric Measurement Adapalene was prepared according to the procedure described above, with the exception that the crude product was stirred twice in a mixture of THF/methanol at 20 C
instead of being refluxed in methanol (as indicated above). This change, however, is not relevant to the final product color. The results of the colorimetric measurement (according to the CIE 1976 L*, a*, b* color space) are illustrated in Tables 2 and 3.
L* a* b*
Value 99.11 -0.52 0.86 Standard Deviation 0.10 0.02 0.06 Number of Replicates: 7 Illuminant: D65 Measurement geometry: 2 White Index (WI E313): 93.85 Table 2 The whiteness of the adapalene sample was then obtained by depositing, leveling and measuring the sample without any special compacting treatment. The results of the whiteness measurement are illustrated in Table 3. It should be noted that the lab coordinates are necessarily different for the same sample since the illuminant used is different.
L* a* b*
Value 97.97 0.24 -0.02 Standard Deviation 0.07 0.03 0.01 Number of Replicates: 3 Illuminant: C
Measurement geometry: 2 White Index (WI E313): 94.35 Table 3 The White Index (WI) was calculated according to ASTM E313-05 "Standard Practice for Calculating Yellowness and Whiteness Indices from Instrumentally Measured Color Coordinates" using the following formula:
WI = Y + (W/,x) (xn ¨ (WLY) (Yn Y") Where: xri and yr, are the chromaticity coordinates for the CIE Standard illuminant and source used, W/,x and ny are numerical coefficients, and Y, x, and y are the luminance factor and the chromaticity coordinates of the specimen (which can be derived from the L, a, b coordinates for a given illuminant and measurement geometry).
Values for all these variable (except those measured for the specimen) are provided in Table 4.
Illuminant/Measurement Geometry D65/2 C/2 xõ 0.3127 0.3101 Yn 0.3290 0.3161 W/,x 800 800 WI,y 1700 1700 Table 4 General Experimental Conditions:
A. Raw Materials The 6-bromo-2-naphthoate and 1-(5-bromo-2-methoxyphenyl)adamantane test solution were prepared by adding 20 mg, accurately weighed, of the substance to be examined into a 100 mL volumetric flask. To the flask was added 5 mL of tetrahydrofuran and the solution was sonicated until the sample dissolved. Next, 60 mL of mobile phase was added, the sample was sonicated again, and the flask was filled to 100 mL with mobile phase.
B. Intermediates and Final Product Test The methyl 643-(1-adamanty1)-4-methoxypheny11-2-naphthoate test solution (t e., adapalene methyl ester) was prepared by adding 20 mg, accurately weighed, of the substance to be examined into a 100 mL volumetric flask. To the flask was added 5 mL of tetrahydrofuran and the solution was sonicated until the sample dissolved. Next, 60 mL of mobile phase was added, the sample was sonicated again, and the flask was filled to 100 mL with mobile phase.
The 643-(1-adamanty1)-4-methoxypheny1]-2-naphthoic acid e., adapalene) or its potassium salt test solution was prepared by adding 20 mg, accurately weighed, of the substance to be examined into a 100 mL volumetric flask. To the flask was added 5 mL of tetrahydrofuran and the solution was sonicated until the sample dissolved. Next, 60 mL of mobile phase was added, the sample was sonicated again, and the flask was filled to 100 mL with mobile phase.
C. Impurities Standard Solutions The impurity 3,3'-diadamanty1-4,41-dimethoxybiphenyl standard solution was prepared by dissolving 20 mg, accurately weighed, of 3,31-diadamanty1-4,4'-dimethoxybiphenyl working standard in 100 mL of tetrahydrofuran in a volumetric flask which was dilutedl mL to 100 mL with mobile phase.
D. Colorimetric Measurement Colorimetric measurements were obtained using two different sets of equipment.
Measurements using illuminant D65 were obtained using a Chroma meter CR-300 (Minolta =
=
brand) and. a measurement geometry of 2 . Measurements using illiiminnnt C
were obtained using a Technibrite ERJC-950TM (Technidyne Corporation) Spectrophotometer and a measurement geometry of 2 .
E. Chromatographic Separation In each of the foregoing examples/steps, the chromatographic separation (i.e., HPLC
analysis) was performed by reversed-phase chromatography in a Symmetry C18 column of 5 pm and 250 x 4.6 mm, using an isocratie system comprising a mobile phase prepared by mixing acetonitrile, tetrahydrofuran, water, trIfluoroacetic acid (43:30:27:0.02 v/v/v/v).
This mobile phase was mixed and filtered through a 022 p.m filter under vacuum. The ehromatograph was equipped with a 235/272 nra dual wavelength detector, and the flow rate was 1.0 mL per minute at room temperature.
Although the invention -has been described and illustrated with a certain degree of particularity, it is understood that the present disclosure has been made only by way of example, and that numerous changes in the conditions and order of steps can be resorted to by those skilled in the art without departing from the scope of the invention.
=
The mixture was heated to approximately 35 C, and 0.13 mL of 1,2-dibromoethane were added to the mixture. Reaction exothermy self-heated the mixture. Next, a solution of 4.85 g of 145-bromo-2-methoxyphenyl)adamantane and 28 mL of tetrahydrofuran was added to the mixture dropwise. During this addition, the temperature of the mixture dropped from reflux temperature to approximately 45 C. The reaction was then stirred for approximately 45 additional minutes at approximately 45 C and was permitted to cool to approximately 22 C. Next, 2.3 g of ZnC12 was added to the mixture, resulting in an exothermic reaction that raised the temperature of the mixture to approximately 38 C. The mixture was then permitted to cool to approximately 22 C and was stirred for approximately 1 hour at this temperature.
Next, 0.03 g of Pd(OAc)2 and 3.5 g of 1-(5-bromo-2-methoxyphenyl) adamantane were added to the mixture, followed by 25 mL of tetrahydrofuran in order to improve agitation, and the mixture was heated at reflux for approximately 24 hours.
The resulting mixture was then evaporated to dryness and poured into 103 mL of 0.015 N HC1.
Next, 150 mL of dichloromethane and 100 mL of water were added to yield a mixture consisting of a solid, an aqueous layer and an organic layer. The mixture was then filtered to separate the solid, the aqueous layer was discarded, and the organic layer was washed with 200 mL of water and decanted again. This process was repeated twice on the filtered solid. The three collected organic layers were evaporated to dryness, washed in methanol, and dried to yield 2.1 g of 3,3'-diadamanty1-4,4'-dimethoxybiphenyl (yield: 39.9%). Analytical data: Melting point: 288.1-289.1 C; Elemental analysis: C 83.63%, H 8.73%; 1H-NMR (300 MHz, CDC13):
8 1.78 (broad s, 12H), 2.08 (broad s, 6H), 2.15 (broad s, 12H), 3.86 (s, 61I), 6.92 (dm, 211, J=8.1 Hz), 7.34 (dd, 2H, J= 2.4, 8.1 Hz), 7.39 (d, 2H, J=2.4 Hz); 13C-NMR
(75.4 MHz, CDC13): 8 29.2, 37.1, 37.2, 40.6, 55.1, 111.9, 125.0, 125.5, 134.0, 138.5, 157.8; MS (El, 70eV): m/z= 484 (6), 483 (36), 412 (M+, 100), 410 (5), 347 (8), 135 (22), 107 (7), 93 (14), 79 (17), 67 (9), 55 (6); IR (Selected absorption bands): 2992, 2964, 2898, 2850, 1603 cm-1.
EXAMPLE 5: Colorimetric Measurement Adapalene was prepared according to the procedure described above, with the exception that the crude product was stirred twice in a mixture of THF/methanol at 20 C
instead of being refluxed in methanol (as indicated above). This change, however, is not relevant to the final product color. The results of the colorimetric measurement (according to the CIE 1976 L*, a*, b* color space) are illustrated in Tables 2 and 3.
L* a* b*
Value 99.11 -0.52 0.86 Standard Deviation 0.10 0.02 0.06 Number of Replicates: 7 Illuminant: D65 Measurement geometry: 2 White Index (WI E313): 93.85 Table 2 The whiteness of the adapalene sample was then obtained by depositing, leveling and measuring the sample without any special compacting treatment. The results of the whiteness measurement are illustrated in Table 3. It should be noted that the lab coordinates are necessarily different for the same sample since the illuminant used is different.
L* a* b*
Value 97.97 0.24 -0.02 Standard Deviation 0.07 0.03 0.01 Number of Replicates: 3 Illuminant: C
Measurement geometry: 2 White Index (WI E313): 94.35 Table 3 The White Index (WI) was calculated according to ASTM E313-05 "Standard Practice for Calculating Yellowness and Whiteness Indices from Instrumentally Measured Color Coordinates" using the following formula:
WI = Y + (W/,x) (xn ¨ (WLY) (Yn Y") Where: xri and yr, are the chromaticity coordinates for the CIE Standard illuminant and source used, W/,x and ny are numerical coefficients, and Y, x, and y are the luminance factor and the chromaticity coordinates of the specimen (which can be derived from the L, a, b coordinates for a given illuminant and measurement geometry).
Values for all these variable (except those measured for the specimen) are provided in Table 4.
Illuminant/Measurement Geometry D65/2 C/2 xõ 0.3127 0.3101 Yn 0.3290 0.3161 W/,x 800 800 WI,y 1700 1700 Table 4 General Experimental Conditions:
A. Raw Materials The 6-bromo-2-naphthoate and 1-(5-bromo-2-methoxyphenyl)adamantane test solution were prepared by adding 20 mg, accurately weighed, of the substance to be examined into a 100 mL volumetric flask. To the flask was added 5 mL of tetrahydrofuran and the solution was sonicated until the sample dissolved. Next, 60 mL of mobile phase was added, the sample was sonicated again, and the flask was filled to 100 mL with mobile phase.
B. Intermediates and Final Product Test The methyl 643-(1-adamanty1)-4-methoxypheny11-2-naphthoate test solution (t e., adapalene methyl ester) was prepared by adding 20 mg, accurately weighed, of the substance to be examined into a 100 mL volumetric flask. To the flask was added 5 mL of tetrahydrofuran and the solution was sonicated until the sample dissolved. Next, 60 mL of mobile phase was added, the sample was sonicated again, and the flask was filled to 100 mL with mobile phase.
The 643-(1-adamanty1)-4-methoxypheny1]-2-naphthoic acid e., adapalene) or its potassium salt test solution was prepared by adding 20 mg, accurately weighed, of the substance to be examined into a 100 mL volumetric flask. To the flask was added 5 mL of tetrahydrofuran and the solution was sonicated until the sample dissolved. Next, 60 mL of mobile phase was added, the sample was sonicated again, and the flask was filled to 100 mL with mobile phase.
C. Impurities Standard Solutions The impurity 3,3'-diadamanty1-4,41-dimethoxybiphenyl standard solution was prepared by dissolving 20 mg, accurately weighed, of 3,31-diadamanty1-4,4'-dimethoxybiphenyl working standard in 100 mL of tetrahydrofuran in a volumetric flask which was dilutedl mL to 100 mL with mobile phase.
D. Colorimetric Measurement Colorimetric measurements were obtained using two different sets of equipment.
Measurements using illuminant D65 were obtained using a Chroma meter CR-300 (Minolta =
=
brand) and. a measurement geometry of 2 . Measurements using illiiminnnt C
were obtained using a Technibrite ERJC-950TM (Technidyne Corporation) Spectrophotometer and a measurement geometry of 2 .
E. Chromatographic Separation In each of the foregoing examples/steps, the chromatographic separation (i.e., HPLC
analysis) was performed by reversed-phase chromatography in a Symmetry C18 column of 5 pm and 250 x 4.6 mm, using an isocratie system comprising a mobile phase prepared by mixing acetonitrile, tetrahydrofuran, water, trIfluoroacetic acid (43:30:27:0.02 v/v/v/v).
This mobile phase was mixed and filtered through a 022 p.m filter under vacuum. The ehromatograph was equipped with a 235/272 nra dual wavelength detector, and the flow rate was 1.0 mL per minute at room temperature.
Although the invention -has been described and illustrated with a certain degree of particularity, it is understood that the present disclosure has been made only by way of example, and that numerous changes in the conditions and order of steps can be resorted to by those skilled in the art without departing from the scope of the invention.
=
19
Claims (25)
1. The use of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a marker for assessing the purity of at least one of adapalene, adapalene methyl ester, an adapalene salt and pharmaceutical compositions containing adapalene.
2. A method for assessing the purity of at least one of adapalene, adapalene methyl ester, an adapalene salt and pharmaceutical compositions containing them comprising the steps of:
(a) providing a standard solution of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
and (b) using the solution as reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity.
(a) providing a standard solution of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
and (b) using the solution as reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity.
3. The method according to claim 2 for assessing the purity of adapalene methyl ester.
4. The method according to claim 2 for assessing the purity of at least one of adapalene and pharmaceutical compositions containing it.
5. The method according to claim 2 for assessing the purity of at least one of an adapalene salt and pharmaceutical compositions containing it.
6. A method for purifying adapalene, or a salt thereof, suitable for pharmaceutical =
use, comprising the steps of:
(a) providing adapalene, or a salt thereof;
(b) assessing the purity of said adapalene, or salt thereof, by using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity; and (c) subjecting the adapalene, or a salt thereof, to one or more purification steps until the 3,3'-diadamantyl-4,4'-dimethoxybiphenyl is not detected, when analyzed according to reverse phase HPLC.
use, comprising the steps of:
(a) providing adapalene, or a salt thereof;
(b) assessing the purity of said adapalene, or salt thereof, by using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity; and (c) subjecting the adapalene, or a salt thereof, to one or more purification steps until the 3,3'-diadamantyl-4,4'-dimethoxybiphenyl is not detected, when analyzed according to reverse phase HPLC.
7. A method for purifying adapalene, or salt thereof, suitable for pharmaceutical use, comprising the steps of:
(a) providing adapalene, or a salt thereof;
(b) assessing the purity of said adapalene, or salt thereof, by using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity; and (c) subjecting the adapalene, or salt thereof, to one or more purification steps;
wherein step (c) is performed either before or after step (b).
(a) providing adapalene, or a salt thereof;
(b) assessing the purity of said adapalene, or salt thereof, by using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity; and (c) subjecting the adapalene, or salt thereof, to one or more purification steps;
wherein step (c) is performed either before or after step (b).
8. The method of claim 7, wherein step (c) is carried out until the adapalene is more than 99.8% pure.
9. The method of claim 7, wherein step (c) is carried out until the adapalene is more than 99.9% pure.
10. The method of claim 6 or 7, wherein the purification step of step (c) comprises at least one of the steps of (i) suspending or recrystallizing solid adapalene, or salt thereof, in an organic solvent; and (ii) dissolving the 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity in an aromatic apolar solvent.
11. The method of claim 10, wherein the aromatic apolar solvent is toluene.
12. The method of claim 10, wherein the organic solvent is at least one of an aromatic hydrocarbon solvent, a ketone solvent, an ether solvent, an alcohol solvent, an ester solvent, and mixtures thereof.
13. A method for preparing adapalene suitable for pharmaceutical use comprising:
(a) preparing adapalene methyl ester;
(b) hydrolyzing said adapalene methyl ester to yield adapalene salt;
(c) converting said adapalene salt into adapalene;
(d) isolating said adapalene; and (e) assessing the purity of at least one of adapalene, adapalene methyl ester, and adapalene salt, by using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity.
(a) preparing adapalene methyl ester;
(b) hydrolyzing said adapalene methyl ester to yield adapalene salt;
(c) converting said adapalene salt into adapalene;
(d) isolating said adapalene; and (e) assessing the purity of at least one of adapalene, adapalene methyl ester, and adapalene salt, by using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity.
14. The method of claim 13, wherein step (e) comprises assessing the purity of adapalene.
15. The method of claim 13, wherein step (e) comprises assessing the purity of adapalene methyl ester.
16. The method of claim 13, wherein step (e) comprises assessing the purity of adapalene salt.
17. A method for preparing adapalene suitable for pharmaceutical use comprising:
(a) preparing an adapalene salt;
(b) converting said adapalene salt into adapalene;
(c) isolating said adapalene; and (d) assessing the purity of at least one of adapalene and adapalene salt, by using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity.
(a) preparing an adapalene salt;
(b) converting said adapalene salt into adapalene;
(c) isolating said adapalene; and (d) assessing the purity of at least one of adapalene and adapalene salt, by using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity.
18. The method of claim 6, 7, 13 or 17, wherein the adapalene salt is the sodium salt, potassium salt, lithium salt, or cesium salt.
19. A method for determining the purity of adapalene suitable for pharmaceutical use, said method comprising:
(a) producing adapalene;
(b) quantifying the amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl in a sample of the adapalene, using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker; and (c) verifying that the adapalene produced in step (a) is suitable for pharmaceutical use, by determining that the sample measured in step (b) has no detectable amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl with respect to adapalene, when analyzed according to reverse phase HPLC.
(a) producing adapalene;
(b) quantifying the amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl in a sample of the adapalene, using 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker; and (c) verifying that the adapalene produced in step (a) is suitable for pharmaceutical use, by determining that the sample measured in step (b) has no detectable amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl with respect to adapalene, when analyzed according to reverse phase HPLC.
20. A method for producing adapalene suitable for pharmaceutical use, said method comprising:
(a) preparing adapalene salt;
(c) converting said adapalene salt into adapalene;
(d) isolating said adapalene;
(e) quantifying the amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl in a sample of the isolated adapalene, using a standard solution of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker; and (f) verifying that the adapalene isolated in step (d) is suitable for pharmaceutical use, by determining that the sample measured in step (e) has no detectable amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl with respect to adapalene, when analyzed according to reverse phase HPLC.
(a) preparing adapalene salt;
(c) converting said adapalene salt into adapalene;
(d) isolating said adapalene;
(e) quantifying the amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl in a sample of the isolated adapalene, using a standard solution of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker; and (f) verifying that the adapalene isolated in step (d) is suitable for pharmaceutical use, by determining that the sample measured in step (e) has no detectable amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl with respect to adapalene, when analyzed according to reverse phase HPLC.
21. The method of claim 6, 7, 13, 17, or 19, wherein the use of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl as a reference marker comprises providing a standard solution of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl and using the solution as a reference marker to determine the level of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl impurity.
22. A method for preparing adapalene suitable for pharmaceutical use comprising:
(a) providing an adapalene salt containing 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
(b) purifying the adapalene salt to a purity of more than 99.8% when analyzed according to reverse phase high performance liquid chromatography with respect to 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
(c) neutralizing the resulting adapalene salt; and (d) isolating from the neutralized salt said adapalene suitable for pharmaceutical use.
(a) providing an adapalene salt containing 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
(b) purifying the adapalene salt to a purity of more than 99.8% when analyzed according to reverse phase high performance liquid chromatography with respect to 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
(c) neutralizing the resulting adapalene salt; and (d) isolating from the neutralized salt said adapalene suitable for pharmaceutical use.
23. The method of claim 22, wherein the adapalene isolated in step (d) does not contain a detectable amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl with respect to adapalene when analyzed according to reverse phase HPLC.
24. A method for preparing adapalene suitable for pharmaceutical use comprising:
(a) providing adapalene methyl ester containing 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
(b) converting the adapalene methyl ester to an adapalene salt having a purity of more than 99.8% when analyzed according to reverse phase high performance liquid chromatography with respect to 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
(c) neutralizing the resulting adapalene salt; and (d) isolating from the neutralized salt said adapalene suitable for pharmaceutical use.
(a) providing adapalene methyl ester containing 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
(b) converting the adapalene methyl ester to an adapalene salt having a purity of more than 99.8% when analyzed according to reverse phase high performance liquid chromatography with respect to 3,3'-diadamantyl-4,4'-dimethoxybiphenyl;
(c) neutralizing the resulting adapalene salt; and (d) isolating from the neutralized salt said adapalene suitable for pharmaceutical use.
25. The method of claim 24, wherein the adapalene isolated in step (d) does not contain a detectable amount of 3,3'-diadamantyl-4,4'-dimethoxybiphenyl with respect to adapalene when analyzed according to reverse phase HPLC.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69125905P | 2005-06-17 | 2005-06-17 | |
| US60/691,259 | 2005-06-17 | ||
| PCT/IB2006/003987 WO2007072217A2 (en) | 2005-06-17 | 2006-06-16 | Process for the preparation of adapalene and related compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2612497A1 CA2612497A1 (en) | 2007-06-28 |
| CA2612497C true CA2612497C (en) | 2015-10-06 |
Family
ID=38189034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2612497A Expired - Fee Related CA2612497C (en) | 2005-06-17 | 2006-06-16 | Process for the preparation of adapalene and related compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8119834B2 (en) |
| EP (1) | EP1902010B1 (en) |
| AR (1) | AR058009A1 (en) |
| AT (1) | ATE535506T1 (en) |
| CA (1) | CA2612497C (en) |
| ES (1) | ES2378085T3 (en) |
| PL (1) | PL1902010T3 (en) |
| SI (1) | SI1902010T1 (en) |
| WO (1) | WO2007072217A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2612497C (en) * | 2005-06-17 | 2015-10-06 | Medichem, S.A. | Process for the preparation of adapalene and related compounds |
| WO2007125542A2 (en) * | 2006-05-03 | 2007-11-08 | Usv Limited | A process for preparation of adapalene |
| CN112479867B (en) * | 2020-12-30 | 2024-03-29 | 武汉诺安药业有限公司 | Chemical preparation method for micronization of adapalene |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU85849A1 (en) * | 1985-04-11 | 1986-11-05 | Cird | BENZONAPHTHALENIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE PHARMACEUTICAL AND COSMETIC FIELDS |
| FR2636061B1 (en) * | 1988-09-07 | 1990-11-09 | Cird | PROCESS FOR THE PREPARATION OF ADAMANTANE-1 DERIVATIVES |
| ATE417610T1 (en) | 2002-03-12 | 2009-01-15 | Galderma Res & Dev | COMPOSITION CONTAINING 6-Ä3-(1-ADAMANTYL)-4-METHOXYPHENYLÜ-2-NAPHTHANOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISEASES |
| AU2006233810B2 (en) | 2005-04-08 | 2011-02-17 | Galderma Research & Development | New method for the preparation of 6-(3-(1-adamantyl)-4-methoxphenyl)-2-naphthoic acid |
| CA2612497C (en) * | 2005-06-17 | 2015-10-06 | Medichem, S.A. | Process for the preparation of adapalene and related compounds |
-
2006
- 2006-06-16 CA CA2612497A patent/CA2612497C/en not_active Expired - Fee Related
- 2006-06-16 ES ES06848698T patent/ES2378085T3/en active Active
- 2006-06-16 PL PL06848698T patent/PL1902010T3/en unknown
- 2006-06-16 US US11/922,353 patent/US8119834B2/en not_active Expired - Fee Related
- 2006-06-16 EP EP06848698A patent/EP1902010B1/en active Active
- 2006-06-16 AT AT06848698T patent/ATE535506T1/en active
- 2006-06-16 SI SI200631276T patent/SI1902010T1/en unknown
- 2006-06-16 WO PCT/IB2006/003987 patent/WO2007072217A2/en active Application Filing
- 2006-06-20 AR ARP060102631A patent/AR058009A1/en unknown
-
2012
- 2012-01-27 US US13/359,793 patent/US8871972B2/en not_active Expired - Fee Related
-
2014
- 2014-10-06 US US14/507,114 patent/US20150141696A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2378085T3 (en) | 2012-04-04 |
| US20130030214A1 (en) | 2013-01-31 |
| EP1902010A2 (en) | 2008-03-26 |
| EP1902010B1 (en) | 2011-11-30 |
| ATE535506T1 (en) | 2011-12-15 |
| US8119834B2 (en) | 2012-02-21 |
| US20150141696A1 (en) | 2015-05-21 |
| WO2007072217A2 (en) | 2007-06-28 |
| CA2612497A1 (en) | 2007-06-28 |
| SI1902010T1 (en) | 2012-07-31 |
| PL1902010T3 (en) | 2012-04-30 |
| WO2007072217A3 (en) | 2007-11-01 |
| US8871972B2 (en) | 2014-10-28 |
| AR058009A1 (en) | 2008-01-23 |
| US20090131713A1 (en) | 2009-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2478302T3 (en) | Ibandronate Polymorph A | |
| JPH1192423A (en) | Production of methyl ester or ethyl ester of trifluoroacetic acid and chlorodifluoroacetic acid | |
| CN106278982B (en) | It is used to prepare the new method of prostaglandin amide | |
| CA2612497C (en) | Process for the preparation of adapalene and related compounds | |
| JP2021161114A (en) | Methylation of Mcl-1 compound | |
| CN101863948A (en) | High-purity (2 beta, 3 alpha, 5 alpha, 16 beta, 17 beta)-2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol or composition thereof and preparation method thereof | |
| CN102686557A (en) | Process for preparing a phenylalanine derivative | |
| CN102924474B (en) | Preparation method of crystal form I of clopidogrel hydrogen sulfate | |
| WO2014068333A2 (en) | New process | |
| Tirado-Rives et al. | Synthesis and structures of stilbene cycles. 2. Low-valent titanium-induced ring closures of aromatic bis (carbonyls) | |
| JP6773693B2 (en) | How to prepare Orchipraz | |
| CN110234622A (en) | For synthesizing the novel method of 1- aryl -1- trifluoromethyl cyclopropane | |
| CN107540655A (en) | A kind of new preparation S（Perfluoroalkyl）The method of dibenzothiophenes fluoroform sulphonate | |
| KR101027945B1 (en) | Recrystallization process of sarpogrelate HCl | |
| WO2011141928A1 (en) | Process for the preparation of highly pure bexarotene | |
| CN106349229B (en) | The preparation method and midbody compound of Lei Dipawei intermediates | |
| KR101134021B1 (en) | Manufacturing method of pitavastatin hemicalcium using novel intermediates | |
| CN104974188B (en) | A kind of tenofovir disoproxil crystal form and preparation method thereof | |
| CN113121578B (en) | Preparation method of benzoborazole compound | |
| KR100911720B1 (en) | A process for preparing crystal foam of sarpogrelate hcl | |
| CN112552200B (en) | Preparation method of optical pure 4- (1-amino) ethyl benzoate and salt thereof | |
| SU906987A1 (en) | Process for preparing 5r-(+)-norbornene-2-carboxylic acid | |
| CN118047762A (en) | Preparation method of rizatriptan EP impurity C | |
| RU2005717C1 (en) | Process for preparing aralkylamine derivatives or their acid addition salts | |
| WO2018203525A1 (en) | Process of preparing iosimenol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210616 |